title: Effect of chromium tripicolinate supplementation on porcine immune response during the periparturient and neonatal period.
abstract: A total of 36 gilts were used to assess the effects of Cr tripicolinate supplementation on immune response in sows and their offspring during the periparturient and neonatal period. Gilts were raised from weaning to reproductive age on diets with either 0 (-Cr) or 200 (+Cr) ppb supplemental Cr from CrPic. Subsequently, 22 gilts (9 -Cr and 13 +Cr) in parity 1 and 16 sows in parity 2 (7 -Cr and 9 +Cr) underwent immune status testing. Only sows that completed all procedures in parity 1 were included in parity 2. Sows were immunized with ovalbumin about 3 wk (d 0), and again 14 d later for gilts, prior to anticipated farrowing, and serum was collected on d 0 and at 14-d intervals for a total of four samples. Serum was collected from five to six pigs/litter at 24 h after birth, three or six pigs/litter the day after weaning (25 d of age) in parity 1, and three pigs/litter the day of weaning (20 d of age) in parity 2. Milk was collected at 1 h (colostrum), 6.5 d (early), and 19 d (late) after farrowing. The only effect of Cr on total immunoglobulin (Ig) concentration was on sow serum IgG (21.7 and 24.1 mg/mL for -Cr and +Cr, respectively; P = 0.08) and IgM (11.0 and 12.5 mg/mL; P = 0.06) on d 0. No effect (P > 0.15) of Cr was observed on the IgG antibody response to ovalbumin, but Cr was associated (P < 0.10) with a decreased IgM antibody response to ovalbumin beginning on d 14. In parity 2, colostral total IgG increased (80.6 and 92.4 mg/mL for parity 1 and 2, respectively; P = 0.06), which was reflected in the neonates at 24 h after birth (33.6 and 39.7 mg/mL; P = 0.01) and at weaning (7.3 and 13.3 mg/mL; P < 0.001). Supplementation of Cr tripicolinate had minimal effects on humoral antibody response of the dam or its transfer to the neonate; however, parity greatly influenced the concentrations of immunoglobulins in the milk and their transfer to the neonate.
authors.affiliation: University of Kentucky, Lexington 40546-0215, USA.
authors.forename: J L G
authors.initials: JL
authors.lastname: van de Ligt
authors.forename: M D
authors.initials: MD
authors.lastname: Lindemann
authors.forename: R J
authors.initials: RJ
authors.lastname: Harmon
authors.forename: H J
authors.initials: HJ
authors.lastname: Monegue
authors.forename: G L
authors.initials: GL
authors.lastname: Cromwell
mesh_terms: D000818:Animals; D000831:Animals, Newborn / Q000276:immunology; D003126:Colostrum / Q000276:immunology; D019587:Dietary Supplements; D005260:Female; D007112:Immunity, Maternally-Acquired / Q000187:drug effects*; D007074:Immunoglobulin G / Q000096:biosynthesis* / Q000097:blood / Q000187:drug effects; D007075:Immunoglobulin M / Q000096:biosynthesis / Q000097:blood / Q000187:drug effects; D007743:Labor, Obstetric / Q000187:drug effects / Q000276:immunology*; D007774:Lactation; D008297:Male; D008892:Milk / Q000276:immunology; D010047:Ovalbumin / Q000276:immunology; D010298:Parity; D010848:Picolinic Acids / Q000008:administration & dosage* / Q000494:pharmacology; D011247:Pregnancy; D013312:Stress, Physiological / Q000276:immunology / Q000662:veterinary; D013552:Swine / Q000276:immunology*
chemical_list: D007074:Immunoglobulin G; D007075:Immunoglobulin M; D010848:Picolinic Acids; C079689:chromium tripicolinate; D010047:Ovalbumin